[1] [1] ZHENG Rongshou, SUN Kexin, ZHANG Siwei, et al. Prevalence of malignant tumors in China in 2015［J］. Chinese Journal of Cancer, 2019, 41(1): 19-28.

[2] [2] CUNLI Y, BIN H, XI Y, et al. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review［J］. World Journal of Surgical Oncology, 2023, 21(1): 5.

[3] [3] FANG Ming. Inhibition of proliferation, invasion and migration of lung squamous cell cells by miR-556-3p targeting NUAK1［D］. Nanchang: Nanchang University, 2021.

[4] [4] CHANG Y, SU M, FENG L, et al. Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose-induced oncogenic effect by downregulating the Warburg effect［J］. Medical Oncology, 2023, 40(10): 297.

[5] [5] HOLM T M, YEO S, TURNER K M, et al. Targeting autophagy in thyroid cancer: EMT, apoptosis, and cancer stem cells［J］. Frontiers in Cell and Developmental Biology, 2022,10: 821855.

[6] [6] LUO Xiangchong. Clinical research progress of antirotinib in the treatment of lung cancer［J］. Chinese Journal of Tumor Biotherapy, 2019, 26(6): 710-714

[7] [7] JAYSON G C, KERBEL R, ELLIS L M, et al. Antiangiogenic therapy in oncology: current status and future directions［J］. Lancet, 2016, 388(10043): 518-529.

[8] [8] BABINA I S, TURNER N C. Advances and challenges in targeting FGFR signalling in cancer［J］. Nature Reviews Cancer, 2017, 17(5): 318-332.

[9] [9] XIAO Lin, WANG Zhiwu, LIU Chunqiu, et al. Evolution of TCM syndrome elements and syndrome types before and after treatment of advanced non-small cell lung cancer with arotinib［J］. Journal of Chinese Medicine, 2020, 26(2): 5.

[10] [10] WANG M, ZHU J, ZHAO F, et al. Transcriptome analyses identify a metabolic gene signature indicative of antitumor immunosuppression of EGFR wild type lung cancers with low PD-L1 expression ［J］. Frontiers in Oncology, 2021, 11: 643503.

[11] [11] JIANG Ling, LIN Zhiyi, LI Na, et al. Correlation between expression of PD-1/PD-L1 and EGFR mutation in non-small cell lung cancer［J］. Chinese Journal of Lung Cancer, 2021, 24(9): 623-631.

[12] [12] WU Baojun, WANG Zhuo, DONG Yu, et al. Identification and single cell sequencing of rare tumor cells in malignant pleural effusion of lung cancer［J］. Genetics, 2019, 41(2): 175-184.

[13] [13] MO Yijun, ZHANG Jianhua, YAN Jun, et al. Targeting programmed death molecule-1 inhibitors in the treatment of advanced squamous non-small cell lung cancer: a report of 2 cases and literature review［J］. Clinical Review, 2019, 34(3): 237-243.

[14] [14] WU Yajuan, ZHAO Jun, JIANG Leilei, et al. Failure pattern and clinical significance of combined radiotherapy after targeted therapy for advanced non-small cell lung cancer［J］. Chinese Journal of Radiology and Protection, 2019, 39(2): 113-120.

[15] [15] YU M, CHEN S, HONG W, et al. Prognostic role of glycolysis for cancer outcome: evidence from 86 studies［J］. Journal of Cancer Research and Clinical Oncology, 2019, 145(4): 967-999.

[16] [16] XIE C, WAN X, QUAN H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor［J］. Cancer Science, 2018, 109(4): 1207-1219.

[17] [17] HE C, WU T, HAO Y. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway［J］. Biochemical and Biophysical Research Communications, 2018, 503(4): 3093-3099.

[18] [18] LIU Xibang, ZHU Linzhi, JIAO Demin, et al. Anlotinib combined with chloroquine promotes apoptosis of human non-small cell lung cancer cell line H1299［J］. Basic Medicine and Clinic, 2021, 41(7): 1018-1023.

[19] [19] WU Guocheng, CHEN Huan. Berberine regulates glycolysis in non-small cell lung cancer cells and inhibits EMT in A549 cells ［J］. Journal of Clinical Pulmonology, 2020, 25(8): 1206-1211.

[20] [20] CUI H, GAO Q, ZHANG L, et al. Knockdown of FOXK1 suppresses liver cancer cell viability by inhibiting glycolysis［J］. Life Sciences, 2018, 213: 66-73.

[21] [21] GUIDO C, WHITAKER-MENEZES D, CAPPARELLI C, et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with “Warburg-like” cancer metabolism and L-lactate production［J］. Cell Cycle, 2012, 11(16): 3019-3035.

[22] [22] TANG Y, DURAND S, DALLE S, et al. EMT-Inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment［J］. Cancers (Basel), 2020, 12(8): 2154.

[23] [23] ZHA Z, LI J. MicroRNA-125a-5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1 ［J］. International Journal of Molecular Medicine, 2020, 46(5): 1849-1861.

[24] [24] TIAN S, PENG P, LI J, et al. SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway［J］. Aging (Albany NY), 2020, 12(4): 3574-3593.

[25] [25] DU L, LI X, ZHEN L, et al. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway［J］. Molecular Medicine Reports, 2018, 17(5): 7163-7169.

[26] [26] LI J, ZHANG J T, JIANG X, et al. The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer［J］. International Journal of Oncology, 2015, 46(5): 2107-2115.

[27] [27] CHEN S, ZHAO E. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma［J］. Clinics and Research in Hepatology and Gastroenterology, 2021, 45(5): 101587.

[28] [28] DE MARCONDES P G, MORGADO-DíAZ J A. The role of EphA4 signaling in radiation-induced EMT-like phenotype in colorectal cancer cells［J］. Journal of Biological Chemistry, 2017, 118(3): 442-445.